| Autor: |
Desoubeaux G; a Université François-Rabelais , Tours , France.; b INSERM, Center d'Etude des Pathologies Respiratoires , Tours , France.; c Centre Hospitalo-Universitaire de Tours , Tours , France., Reichert JM; d The Antibody Society , Framingham , MA , USA.; e Reichert Biotechnology Consulting LLC , Framingham MA , USA., Sleeman M; f MedImmune , Cambridge , UK., Reckamp KL; g City of Hope, Comprehensive Cancer Center , Duarte , CA , USA., Ryffel B; h Université d'Orléans , Orléans , France.; i University of Cape Town, Institute of Infectious Disease and Molecular Medicine (IDM) , Cape Town , South Africa., Adamczewski JP; j Sanofi R&D , Chilly-Mazarin , France., Sweeney TD; k Nektar Therapeutics , San Francisco CA , USA., Vanbever R; l Université Catholique de Louvain, Louvain Drug Research Institute , Brussels , Belgium., Diot P; a Université François-Rabelais , Tours , France.; b INSERM, Center d'Etude des Pathologies Respiratoires , Tours , France.; c Centre Hospitalo-Universitaire de Tours , Tours , France., Owen CA; m Harvard Medical School, Brigham and Women's Hospital , Boston , MA , USA.; n Lovelace Respiratory Research Institute , Albuquerque , NM , USA., Page C; o King's College, Sackler Institute of Pulmonary Pharmacology , London , UK., Lerondel S; p PHENOMIN-TAAM CNRS, CIPA , Orléans , France., Le Pape A; a Université François-Rabelais , Tours , France.; b INSERM, Center d'Etude des Pathologies Respiratoires , Tours , France.; p PHENOMIN-TAAM CNRS, CIPA , Orléans , France., Heuze-Vourc'h N; a Université François-Rabelais , Tours , France.; b INSERM, Center d'Etude des Pathologies Respiratoires , Tours , France. |
